3 of 3 daily views used · 0 remaining. Refreshes and chart changes do not use another view.
Daily close · 2026-10-12
Price return
Both stocks start at 0% on the first shared trading day.
CELC274.79%
CLRB-99.48%
Use left and right arrow keys to inspect historical line observations. Financial bars can be focused individually.
Split-adjusted closing prices. Dividends are excluded.Explore stocks within your daily allowance.
Similarity
100.0%
4 shared / 4 total tags
How similar are their businesses?
The score compares business activities in annual filings released in 2025. Core activities receive four times the weight of material activities. Industries that fewer companies share carry more weight.
Positive activities from the two selected annual filings. Up to six activities per group are shown here; every activity remains in the complete table. These are classification sets, not revenue shares. The weighted similarity score also accounts for exposure and how common each activity is.Show business activity table · 4 rows, 3 columns
Core activities receive full weight; material activities receive one quarter. Select a tag to read the filing evidence.
Business activity
CELC
CLRB
Core
Core
Core
Core
Core
Core
Core
Core
What each company does
Compare the businesses
CS
Celcuity Inc. Common Stock
CELC · XNAS
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Price return uses split-adjusted daily closes and excludes dividends. Both stocks start on the first shared trading day within the selected window. Unavailable metrics leave gaps.
Financials use SEC canonical statements available by the displayed cutoff, retaining each company's fiscal period end. Annual and quarterly amounts are shown separately. P/E is unavailable when earnings do not support a positive ratio.
Business overlap uses industry tags from annual filings released in 2025. Each core activity receives full weight; each material activity receives one quarter of that weight. Rarer industries carry more weight. We sum the smaller exposure for each shared activity and divide it by the sum of the larger exposure for every activity in either company. This measures business overlap, rather than price correlation or expected returns.
Related comparisons require a shared specific core activity and at least 20% overlap. Broad categories alone do not establish a close peer relationship. Identical classifications can score 100% even when companies sell different products. We select up to ten leading peers per issuer for discovery, combine both directions, and require current common shares, public company profiles and stored price observations. Arbitrary stock pairs remain available.
Statements available through 2026-10-14. Industry snapshot: 2025-12-31 · 5,721 classified issuers.